期刊
HEART FAILURE CLINICS
卷 10, 期 3, 页码 453-+出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.hfc.2014.04.006
关键词
Heart failure; Cardiac natriuretic peptides; B-type natriuretic peptide; N-terminal prohormone B-type natriuretic peptide; Diagnosis; Prognosis
资金
- Roche Diagnostics
- Alere
- Critical Diagnostics
- Siemens
- Thermo Fisher
- Singulex
- Zensun
- Amgen
- Novartis
- St. Jude Medical
Timely diagnosis, early introduction of appropriate treatment, accurate risk stratification, and optimal titration of therapy are all key to the management of acute and chronic heart failure (HF). Plasma concentrations of the cardiac natriuretic peptides (NPs) are valuable aids in each of these elements of care. However, most data are derived from cohorts with undifferentiated HF or HF with reduced ejection fraction (HFREF), and the performance and best application of NPs in HF with preserved ejection fraction (HFPEF) is less certain. This review outlines the evidence for use of NPs in the evaluation and management of HFPEF.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据